



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 13 February 2026

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir/Madam,

Sub: - Execution of Agreement with NXI Therapeutics AG

Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015

.....

Pursuant to Regulation 30 read with other applicable provisions of the SEBI Listing Regulations, we wish to inform that Shilpa Medicare Limited ('SML') has entered into a binding agreement with NXI Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE).

Details with respect to the above-mentioned event as required under Regulation 30 of Schedule III of the SEBI Listing Regulations and SEBI Circular dated 13th July 2023 are provided in Annexure I to this letter.

The above information is also available on the website of the Company www.vbshilpa.com

This is for your information and records.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbsilpa.com, Web: www.vbsilpa.com

CIN: L85110KA1987PLC008739

Annexure I

Sl. No.	Particulars	Remarks
1.	Name of the entity	NXI Therapeutics AG, a Switzerland Company
2.	Area of agreement/ JV	A binding Agreement to develop, manufacture and supply for an NCE.
3.	Whether the Order/Contract has been awarded by domestic/international entity	International entity
4.	Share exchange ratio/ JV ratio	Not Applicable
5.	Scope of business operation of agreement/ JV	Scope of Agreement includes development and supply of a Novel asset including commercial supply across territories
6.	Details of consideration paid/ received in agreement/ JV	Not Applicable
7.	Significant terms and conditions of the Order/Contract awarded in brief	Under the terms of the strategic collaboration, SML will support both development – including first-in-human clinical studies – as well as long-term commercial supply with GMP manufacturing.
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	NXI Therapeutics AG is not a related party to the SML or promoter/ promoter group/ group companies.
9.	Size of the Entity	Not Applicable
10.	Rationale and benefit expected	Ability to develop, manufacture and supply novel asset which is critical in treatment for Autoimmune conditions. Also, this arrangement is expected to strengthen SML capability and know-how in the innovative side of therapies.

Shilpa Medicare Enters into Strategic Partnership with NXI Therapeutics AG for Novel Asset Targeting Autoimmune and Alloimmune Disorders

Third major international mandate in recent months reinforces accelerating biotech traction and long-term revenue visibility

Karnataka, India & Basel, Switzerland 13th February 2026:

Shilpa Medicare Limited (BSE/NSE: SHILPAMED), a global integrated pharmaceutical and CDMO company, today announced the strategic partnership for a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland for a novel therapy targeting autoimmune and alloimmune disorders.

Under the terms of agreement, Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.

The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential.

This partnership marks the third significant international development and manufacturing contract secured by Shilpa group, underscoring strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.

While financial terms remain confidential, the agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.

Mr. Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited, commented:

"This collaboration reinforces Shilpa's transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform."



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Dr. Ruben Herrendorff, CEO, NXI Therapeutics AG, added:

"Shilpa's scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones."

With expanding biologics capabilities, advanced GMP facilities in India, and increasing global biotech engagements, Shilpa continues to strengthen its position as a trusted development and commercial manufacturing partner in high-growth therapeutic segments.

About Shilpa Medicare Limited

Shilpa Medicare Limited is a global pharmaceutical company and integrated CDMO providing end-to-end solutions across small molecules, biologics, and complex therapeutics. The company partners with innovators worldwide to support development through commercialization, with a growing focus on high-value specialty and biologics programs.

About NXI Therapeutics

NXI Therapeutics is a Swiss biotechnology company with a global, long-term perspective, focused on developing the next generation of safe immunotherapies. It aims to truly change the course of autoimmune and alloimmune conditions by realizing powerful targeted immunomodulation that preserves immunocompetence.